BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 18268285)

  • 21. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
    Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
    Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
    Höglund M; Brune M; Sallerfors B; Ahlgren T; Billström R; Hedenus M; Markevärn B; Nilsson B; Simonsson B; Stockelberg D; Wahlin A
    Bone Marrow Transplant; 2003 Dec; 32(12):1119-24. PubMed ID: 14647265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
    Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
    Samaras P; Buset EM; Siciliano RD; Haile SR; Petrausch U; Mischo A; Honegger H; Pestalozzi BC; Schanz U; Stussi G; Stahel RA; Knuth A; Renner C; Stenner-Liewen F
    Oncology; 2010; 79(1-2):93-7. PubMed ID: 21079406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
    Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
    Hosing C; Qazilbash MH; Kebriaei P; Giralt S; Davis MS; Popat U; Anderlini P; Shpall EJ; McMannis J; Körbling M; Champlin RE
    Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
    Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
    Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ; Sweetenham JW
    Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
    Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.
    Willis F; Woll P; Theti D; Jamali H; Bacon P; Baker N; Pettengell R
    Bone Marrow Transplant; 2009 Jun; 43(12):927-34. PubMed ID: 19169289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
    Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
    Donato ML; Gershenson D; Ippoliti C; Wharton JT; Bast RC; Aleman A; Anderlini P; Gajewski JG; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin RE
    Bone Marrow Transplant; 2000 Jun; 25(11):1137-40. PubMed ID: 10849525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.